Skip to main content

Table 6 Comparisons between ctDNA progression, radiologic progression, and CA19-9 progression

From: High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study

Comparison

Value

ctDNA progression vs radiologic progression

 ctDNA progression earlier

15 (48.4)

 Lead time (days)

60 (28–94)

 On the same day

11 (35.5)

 Radiologic progression earlier

5 (16.1)

ctDNA progression vs CA19-9 progression

 ctDNA progression earlier

13 (41.9)

 Lead time (days)

58 (44–93)

 On the same day

15 (48.4)

 CA19-9 progression earlier

3 (9.7)

  1. Continuous variables are shown as median (interquartile range), and categorical variables as count (percentage [%])